PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

Seminars in Cancer Biology

Volumn 48, Issue , 2018, Pages 91-103

  O'Donnell, Jake S ^a,b   Massi, Daniela ^c   Teng, Michele W L ^a,b   Mandala, Mario ^c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

AKT; Combination therapy; Immunotherapeutic resistance; Immunotherapy; Inhibitors; mTOR; PI3K; Targeted therapy; Tumor microenvironment

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFURESERTIB; ALPELISIB; BIMIRALISIB; BUPARLISIB; CAPIVASERTIB; CAPMATINIB; CETUXIMAB; ERLOTINIB; EVEROLIMUS; FIMEPINOSTAT; GEDATOLISIB; GSK 2636771; INCB 050465; ITACITINIB; LAPATINIB; LENVATINIB; LETROZOLE; LUMINESPIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MIRANSERTIB; MSC 2363318A; NILOTINIB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PQR 30; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RIBOCICLIB; SAPANISERTIB; SELUMETINIB; SERABELISIB; SORAFENIB; SOTRASTAURIN; TAMOXIFEN; TASELISIB; TRAMETINIB; UNINDEXED DRUG; UPROSERTIB; VISTUSERTIB; WX 037; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADENOID CYSTIC CARCINOMA; AKT SIGNALING; ASTHENIA; BILE DUCT CANCER; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CARCINOMA; CELL FUNCTION; COLORECTAL CANCER; DIARRHEA; DRUG EFFECT; DRUG TARGETING; EFFECTOR CELL; ENZYME INHIBITION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEVER; GLIOBLASTOMA; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; KAPOSI SARCOMA; LIVER CANCER; LIVER DYSFUNCTION; LYMPHOMA; MALIGNANT NEOPLASM; MUCOSA INFLAMMATION; NAUSEA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PERITONEUM CANCER; PNEUMONIA; RASH; RENAL CELL CARCINOMA; REVIEW; SALIVARY GLAND CARCINOMA; SOLID MALIGNANT NEOPLASM; STOMACH CANCER; THYROID CANCER; TOXICITY; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; UTERINE TUBE TUMOR; VOMITING; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PROCEDURES;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES; TUMOR MICROENVIRONMENT;

EID: 85019488076     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2017.04.015     Document Type: Review

References (120)

1. Smyth, M.J., et al. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13:3 (2016), 143–158.
2. Schreiber, R.D., Old, L.J., Smyth, M.J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:6024 (2011), 1565–1570.
3. Brahmer, J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366:26 (2012), 2455–2465.
4. Hodi, F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:8 (2010), 711–723.
5. Topalian, S.L., et al. Safety: activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:26 (2012), 2443–2454.
6. Postow, M.A., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372:21 (2015), 2006–2017.
7. Wolchok, J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369:2 (2013), 122–133.
8. Larkin, J., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med., 2015.
9. Ribas, A., et al. PD-1 blockade expands intratumoral memory t cells. Cancer Immunol. Res. 4:3 (2016), 194–203.
10. Topalian, S.L., et al. Survival, durable tumor remission, and long-Term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol., 2014.
11. Burgering, B.M., Coffer, P.J., Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376:6541 (1995), 599–602.
12. Fruman, D.A., Rommel, C., PI3 K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13:2 (2014), 140–156.
13. Xue, G., et al. Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy. J. Natl. Cancer Inst., 107(7), 2015.
14. Menzies, A.M., Long, G.V., Systemic treatment for BRAF-mutant melanoma: where do we go next?. Lancet Oncol. 15:9 (2014), e371–81.
15. Vanhaesebroeck, B., Stephens, L., Hawkins, P., PI3K signalling: the path to discovery and understanding. Nat. Rev. Mol. Cell Biol. 13:3 (2012), 195–203.
16. Engelman, J.A., Luo, J., Cantley, L.C., The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7:8 (2006), 606–619.
17. Divecha, N., Irvine, R.F., Phospholipid signaling. Cell 80:2 (1995), 269–278.
18. Franke, T.F., et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81:5 (1995), 727–736.
19. Martelli, A.M., et al. The emerging multiple roles of nuclear Akt. Biochim. Biophys. Acta 1823:12 (2012), 2168–2178.
20. Sarbassov, D.D., et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:5712 (2005), 1098–1101.
21. Inoki, K., et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4:9 (2002), 648–657.
22. Song, X., et al. ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas. Cancer Res. 75:6 (2015), 1035–1045.
23. Karakas, B., Bachman, K.E., Park, B.H., Mutation of the PIK3CA oncogene in human cancers. Br. J. Cancer 94:4 (2006), 455–459.
24. Yi, K.H., Lauring, J., Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity. Oncotarget 7:4 (2016), 4241–4251.
25. Steck, P.A., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:4 (1997), 356–362.
26. Li, J., et al. PTEN: a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:5308 (1997), 1943–1947.
27. Pearce, L.R., Komander, D., Alessi, D.R., The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 11:1 (2010), 9–22.
28. Kaneda, M.M., et al. PI3Kgamma is a molecular switch that controls immune suppression. Nature, 2016.
29. Engelman, J.A., Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9:8 (2009), 550–562.
30. Meng, L.H., Zheng, X.F., Toward rapamycin analog (rapalog)-based precision cancer therapy. Acta Pharmacol. Sin. 36:10 (2015), 1163–1169.
31. Cybulski, N., Hall, M.N., TOR complex 2: a signaling pathway of its own. Trends Biochem Sci 34:12 (2009), 620–627.
32. Motzer, R.J., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:9637 (2008), 449–456.
33. Hutson, T.E., et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 32:8 (2014), 760–767.
34. Sarker, D., et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 21:1 (2015), 77–86.
35. Brachmann, S.M., et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol. Cancer Ther. 11:8 (2012), 1747–1757.
36. Chakrabarty, A., et al. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res. 73:3 (2013), 1190–1200.
37. Ihle, N.T., et al. Molecular pharmacology and antitumor activity of PX-866: a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 3:7 (2004), 763–772.
38. Liu, N., et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models. Mol. Cancer Ther. 12:11 (2013), 2319–2330.
39. Ohwada, J., et al. Discovery and biological activity of a novel class I PI3K inhibitor: CH5132799. Bioorg. Med. Chem. Lett. 21:6 (2011), 1767–1772.
40. Foukas, L.C., et al. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc. Natl. Acad. Sci. U. S. A. 107:25 (2010), 11381–11386.
41. Brown, J.R., et al. Idelalisib: an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 123:22 (2014), 3390–3397.
42. Ramanathan, S., et al. Clinical pharmacokinetic and pharmacodynamic profile of idelalisib. Clin. Pharmacokinet. 55:1 (2016), 33–45.
43. Tamura, K., et al. Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 77:4 (2016), 787–795.
44. De Bono, J.S., Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study). ASCO Annual Meeting J Clin Oncol, 2016, 34 (suppl; abstr 5017).
45. Allen, C.E., et al. Evaluation of afuresertib: an oral pan-AKT inhibitor, In patients with langerhans cell histiocytosis. Blood, 122(21), 2013 (2907-2907).
46. Dumble, M., et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS One, 9(6), 2014, e100880.
47. Nitulescu, G.M., et al. Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use (Review). Int. J. Oncol. 48:3 (2016), 869–885.
48. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
49. Fridman, W.H., et al. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12:4 (2012), 298–306.
50. Okkenhaug, K., Signaling by the phosphoinositide 3-kinase family in immune cells. Annu. Rev. Immunol. 31 (2013), 675–704.
51. Ying, H., et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB—Cytokine network. Cancer Discov. 1:2 (2011), 158–169.
52. Dong, Y., et al. PTEN functions as a melanoma tumor suppressor by promoting host immune response. Oncogene 33:38 (2014), 4632–4642.
53. Peng, W., et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discovery 6:2 (2016), 202–216.
54. Dong, Y., et al. PTEN functions as a melanoma tumor suppressor by promoting host immune response. Oncogene 33:38 (2014), 4632–4642.
55. Wada, J., et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res. 29:3 (2009), 881–888.
56. Osada, T., et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57:8 (2008), 1115–1124.
57. Lastwika, K.J., et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 76:2 (2016), 227–238.
58. Song, M., et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One, 8(6), 2013, e65821.
59. Parsa, A.T., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13:1 (2007), 84–88.
60. Mittendorf, E.A., et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2:4 (2014), 361–370.
61. Ribas, A., Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366:26 (2012), 2517–2519.
62. Wherry, E.J., Kurachi, M., Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15:8 (2015), 486–499.
63. Teng, M.W., et al. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 75:11 (2015), 2139–2145.
64. Gowrishankar, K., et al. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-kappaB. PLoS One, 10(4), 2015, e0123410.
65. Abu-Eid, R., et al. Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway. Cancer Immunol. Res. 2:11 (2014), 1080–1089.
66. Gato-Canas, M., et al. A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. Oncotarget 6:29 (2015), 27160–27175.
67. Schmid, M.C., et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma: a single convergent point promoting tumor inflammation and progression. Cancer Cell 19:6 (2011), 715–727.
68. Gonzalez-Garcia, A., et al. Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer. Gastroenterology 138:4 (2010), 1374–1383.
69. Hirsch, E., et al. PI3K in cancer-stroma interactions: bad in seed and ugly in soil. Oncogene 33:24 (2014), 3083–3090.
70. Zou, W., Regulatory T cells: tumour immunity and immunotherapy. Nat. Rev. Immunol. 6:4 (2006), 295–307.
71. Teng, M.W., et al. Biology and clinical observations of regulatory T cells in cancer immunology. Curr. Top. Microbiol. Immunol. 344 (2011), 61–95.
72. Ali, K., et al. Inactivation of PI(3)K p110[dgr] breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510:7505 (2014), 407–411.
73. Patton, D.T., et al. Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4 + CD25 + Foxp3+ regulatory T cells. J. Immunol. 177:10 (2006), 6598–6602.
74. Buck, M.D., O'Sullivan, D., Pearce, E.L., T cell metabolism drives immunity. J. Exp. Med. 212:9 (2015), 1345–1360.
75. Chang, C.H., et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153:6 (2013), 1239–1251.
76. Patsoukis, N., et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun., 6, 2015, 6692.
77. Bengsch, B., et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity 45:2 (2016), 358–373.
78. Robert, C., Hamid, R.A.O., Daud, A., Wolchok, J.D., Joshua, A.M., Hwu, W., Weber, J.S., Gangadhar, T.C., Joseph, R.W., Dronca, R.S., Patnaik, A., Zarour, H.M., Kefford, R., Hersey, P., Li, A., Diede, S.J., Ebbinghaus, S., Hodi, F.S., Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. ASCO Annual Meeting, 2016.
79. Schadendorf, D., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33:17 (2015), 1889–1894.
80. Kim, E.H., Suresh, M., Role of PI3 K/Akt signaling in memory CD8 T cell differentiation. Front. Immunol., 4, 2013, 20.
81. Araki, K., et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460:7251 (2009), 108–112.
82. van der Waart, A.B., et al. Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. Blood 124:23 (2014), 3490–3500.
83. Lazarevic, V., Glimcher, L.H., Lord, G.M., T-bet: a bridge between innate and adaptive immunity. Nat. Rev. Immunol. 13:11 (2013), 777–789.
84. Angelosanto, J.M., et al. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J. Virol. 86:15 (2012), 8161–8170.
85. Yap, T.A., et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 29:35 (2011), 4688–4695.
86. Okkenhaug, K., Vanhaesebroeck, B., PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3:4 (2003), 317–330.
87. Okkenhaug, K., Turner, M., Gold, M.R., PI3K signaling in B cell and T cell biology. Front. Immunol., 5, 2014, 557.
88. Spranger, S., Bao, R., Gajewski, T.F., Melanoma-intrinsic [bgr]-catenin signalling prevents anti-tumour immunity. Nature 523:7559 (2015), 231–235.
89. Tumeh, P.C., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:7528 (2014), 568–571.
90. Zaretsky, J.M., et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375:9 (2016), 819–829.
91. Timmerman, J.M., Levy, R., Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50 (1999), 507–529.
92. Noh, K.H., et al. Activation of Akt as a mechanism for tumor immune evasion. Mol. Ther. 17:3 (2009), 439–447.
93. Karin, M., et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2:4 (2002), 301–310.
94. Ribas, A., et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315:15 (2016), 1600–1609.
95. O'Donnell, J.S., Smyth, M.J., Teng, M.W., Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?. Genome Med., 8(1), 2016, 111.
96. Liu, J., et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 6:12 (2016), 1382–1399.
97. Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348:6230 (2015), 62–68.
98. Crompton, J.G., et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 75:2 (2015), 296–305.
99. Perkins, M.R., et al. Manufacturing an enhanced CAR T cell product by inhibition of the PI3K/Akt pathway during T cell expansion results in improved In vivo efficacy of anti-BCMA CAR t cells. Blood, 126(23), 2015 1893-1893.
100. Grande, S., et al. Abstract 2296: Inhibition of the PI3K/Akt pathway during CAR T cell production results in enhanced efficacy across multiple in vivo tumor models. Cancer Res., 76(14), 2016 2296-2296.
101. Knight, D.A., et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 123:3 (2013), 1371–1381.
102. Perna, D., et al. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc. Natl. Acad. Sci. U. S. A. 112:6 (2015), E536–45.
103. Shao, Y., Aplin, A.E., Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 70:16 (2010), 6670–6681.
104. Cooper, Z.A.et al., Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. Oncoimmunology, 3(9), 2014, e954956.
105. Sweetlove, M., et al. Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-Mutant melanoma cell growth. Front. Oncol., 16(5), 2015, 135.
106. Posch, C., et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 110:10 (2013), 4015–4020.
107. Wisinski, K.B., et al. Phase I study of an AKT inhibitor (MK-2206) combined with lapatinib in adult solid tumors followed by dose expansion in advanced HER2+ breast cancer. Clin. Cancer Res. 22:11 (2016), 2659–2667.
108. O'Brien, S.M., et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood 126:25 (2015), 2686–2694.
109. Boutros, C., et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13:8 (2016), 473–486.
110. Gao, Y., Yuan, C.Y., Yuan, W., Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?. Stem Cell Investig., 3, 2016, 31.
111. Papadopoulos, K.P., et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin. Cancer Res. 20:9 (2014), 2445–2456.
112. Munster, P., et al. First-in-human phase I study of GSK2126458: an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies. Clin. Cancer Res. 22:8 (2016), 1932–1939.
113. Shapiro, G.I., et al. Phase i safety: pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 20:1 (2014), 233–245.
114. Akinleye, A., et al. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol, 6(1), 2013, 88.
115. Burris, H.A., et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study. J. Clin. Oncol., 29(15), 2011 3003-3003.
116. Tabernero, J., et al. First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068. J. Clin. Oncol., 29(15), 2011 3022-3022.
117. Banerji, U., et al. First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors. J. Clin. Oncol., 30(15), 2012 3004-3004.
118. Tabernero, J., et al. Abstract CT-02: A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies. Cancer Res., 72(8), 2012 (CT-02-CT-02).
119. Shapiro, G.I., et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 20:1 (2014), 233–245.
120. Garcia, V.M., et al. A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. J. Clin. Oncol., 29(15), 2011, 3021.